Current status of treatment for early-stage invasive breast cancer;A korai emlorák kezelésének aktuális helyzete

Orvosi Hetilap

Volumn 150, Issue 22, 2009, Pages 1013-1021

  Kásler, Miklós ^a   Polgár, Csaba ^a   Fodor, János ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Adjuvant treatment; Breast cancer; Surgery

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; COMPUTER ASSISTED TOMOGRAPHY; HORMONAL THERAPY; HUMAN; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REVIEW; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANGIOSARCOMA; ARTICLE; AXILLA; BRACHYTHERAPY; BREAST RECONSTRUCTION; BREAST TUMOR; CHEMISTRY; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; PATHOLOGY; RADIATION EXPOSURE; RADIATION INJURY; SECOND CANCER; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BRACHYTHERAPY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEMANGIOSARCOMA; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MAMMAPLASTY; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, COMPUTER-ASSISTED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 67649605041     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28615     Document Type: Review

References (77)

1. Jemal, A., Siegel, R., Ward, E. és mtsai: Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58, 71-96.
2. Ka ́sler M.: Ajánlások az emlorák korszeru diagnosztikájára, kezelésére és gondozására. Magy. Onkol., 2000, 44, 11-13.
3. Kovács A., Döbrössy L., Budai A. és mtsai: Az emloszurés helyzete Magyarországon 2006-ban. Orv. Hetil., 2007, 148, 879-885.
4. Polgár, Cs., Kahán, Zs., Orosz, Z. és mtsai: The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast. Pathol. Oncol. Res., 2008, 14, 179-192.
5. Polgár, Cs., Orosz, Zs., Kahán, Zs. és mtsai: In situ duktális emlo karcinóma (DCIS) kombinált sebészi- és sugárkezelése: a magyarországi multicentrikus prospektív randomizált vizsgálat korai eredményei. Magy. Onkol., 2008, 52, 269-277.
6. Kásler M.: A komplex onkodiagnosztika és onkoterápia irányelvei. Semmelweis Kiadó, Budapest, 2008.
7. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, 2009, www.nccn.org.
8. Clarke, M., Collins, R., Darby, S. és mtsai: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet, 2005, 366, 2087-2106.
9. Whelan, T., MacKenzie, R., Julian, J. és mtsai: Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J. Natl. Cancer, 2002, 94, 1143-1150.
10. Vingh-Hung, V., Verschraegen, C.: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J. Natl. Cancer Inst., 2004, 96, 115-121.
11. Bartelink, H., Horiot, J. C., Poortmans, P. és mtsai: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N. Engl. J. Med., 2001, 345, 1378-1387.
12. Bartelink, H., Horiot, J. C., Poortmans, P. és mtsai: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J. Clin. Oncol., 2007, 25, 3259-3265.
13. Polgár, Cs., Fodor, J., Orosz, Z. és mtsai: Electron and high-doserate brachytherapy boost in the conservative treatment of stage I-II breast cancer. Strahlenther. Onkol., 2002, 178, 615-621.
14. Romestaing, P., Lehingue, Y., Carrie, C. és mtsai: Role of a 10-Gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France. J. Clin. Oncol., 1997, 15, 963-968.
15. Jones, H., Antonini, N., Collette, L. és mtsai: The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial. Int. J. Radiat. Oncol. Biol. Phys., 2007, 69, S2-S3.
16. Polgár, Cs., Fodor, J., Major, T. és mtsai: The role of boost irradiation in the conservative treatment of stage I-II breast cancer. Pathol. Oncol. Res., 2001, 7, 241-250.
17. Huges, K. S., Schnaper, L. A., Berry, D. és mtsai: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med., 2004, 351, 971-977.
18. Polgár, Cs., Fodor, J., Major, T. és mtsai: Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma - 5-year results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 2007, 69, 694-702.
19. Polgár, Cs., Major, T., Fodor, J. és mtsai: High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: sevenyear results of a comparative study. Int. J. Radiat. Oncol. Biol. Phys., 2004, 60, 1173-1181.
20. Polgár, Cs., Strnad, V., Major, T.: Brachytherapy for partial breast irradiation: the European experience. Semin. Radiat. Oncol., 2005, 15, 116-122.
21. Silvestrini, R., Daidone, M. G., Luisi, A. és mtsai: Biologic and clinicopathologic factors as indicators of specifi c relapse types in node-negative breast cancer. J. Clin. Oncol., 1995, 13, 697-704.
22. Elkhuizen, P. H., Voogd, A. C., van der Broek, L. C. és mtsai: Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression. Int. J. Radiat. Oncol. Biol. Phys., 1999, 45, 73-83.
23. Haffty, B. G., Yang, Q., Reiss, M. és mtsai: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol., 2006, 24, 5652-5657.
24. Nguyen, P. L., Taghian, A. G., Katz, M. S. és mtsai: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast conserving therapy. J. Clin. Oncol., 2008, 26, 2373-2378.
25. Fodor, J., Major, T., Polgár, Cs. és mtsai: The impact of radiotherapy on the incidence and time of occurrence of local recurrence in early-stage breast cancer after breast conserving therapy. Neoplasma, 2001, 47, 181-186.
26. Haffty, B. G.: Molecular and genetic markers in the local-regional management of breast cancer. Semin. Radiat. Oncol., 2002, 12, 329-340.
27. Yang, Q., Moran, M. S., Haffty, B. G.: Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res. Treat. (accepted 14 May, 2008).
28. Kroman, N., Holtveg, H., Wohlfahrt, J. és mtsai: Effect of breastconserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer, 2004, 100, 688-693.
29. Bijker, N., Meijnen, P., Peterse, J. L. és mtsai: Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J. Clin. Oncol., 2006, 24, 3381-3387.
30. Emdin, S. O., Granstrand, B., Ringberg, A. és mtsai: SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol., 2006, 45, 536-543.
31. Fisher, E. R., Dignam, J., Tan-Chiu, E. és mtsai: Pathologic fi ndings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: Intraductal carcinoma. Cancer, 1999, 86, 429-438.
32. Viani, G. A., Stefano, E. J., Afonso, S. L. és mtsai: Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat. Oncol., 2007, 2, 28.
33. Omlin, A., Amichetti, M., Azria, D. és mtsai: Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol., 2006, 7, 652-656.
34. Major, T., Fröhlich, G., Lövey, K. és mtsai: Dosimetric experience with accelerated partial breast irradiation using image-guided interstitial brachytherapy. Radiother. Oncol., 2009, 90, 48-55.
35. Major T., Skriba Z., Varjas G. és mtsai: Emlodaganatos betegek külso besugárzási terveinek dozimetriai vizsgálata: a dóziseloírás megválasztá sának jelentosége. Magy. Onkol., 2005, 49, 235-243.
36. Lövey, K., Fodor, J., Szabó, É. és mtsai: Fat necrosis after partialbreast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy - 4-year results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 2007, 69, 724-731.
37. Strobbe, L. J., Peterse, H. L., van Tinteren, H. és mtsai: Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforeseen sequela. Breast Cancer Res. Treat., 1998, 47, 101-109.
38. Yap, J., Chuba, P. J., Thomas, R. és mtsai: Sarcoma as a second malignancy after treatment for breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2002, 52, 1832-1840.
39. Fodor, J., Orosz, Z., Szabó, É. és mtsai: Angiosarcoma after conservation treatment for breast carcinoma: Our experience and a review of the literature. J. Am. Acad. Dermatol., 2006, 54, 499-504.
40. Péley G., Farkas E., Téglás M.: A kettos jelöléses orszemnyirokcsomó biopszia sebészi alkalmazhatósága és pontossága emlorákban. Magy. Seb., 2000, 53, 241-246.
41. Fodor J., Polgár Cs., Péley G. és mtsai: Az axilla kezelése emlorákban: evidenciák és vitatott kérdések. Orv. Hetil., 2001, 142, 1841-1850.
42. Hennequin, C., Romestaing, P., Maylin, C.: Irradiation of lymph nodes areas in breast cancer. Cancer Radiother., 2008, 12, 559-564.
43. Overgaard, M., Hansen, P. S., Overgaard, J. és mtsai: Postoperative radiotherapy for high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N. Engl. J. Med., 1997, 337, 949-955.
44. Overgaard, M., Jensen, M. B., Overgaard, J. és mtsai: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet, 1999, 353, 1641-1648.
45. Ragaz, J., Jackson, S. M., Le, N. és mtsai: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med., 1997, 337, 956-962.
46. Fodor, J., Polgár, Cs., Major, T. és mtsai: Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation: the signifi cance of tumor size. Strahlenther. Onkol., 2003, 179, 197-202.
47. McGuire, S. E., Gonzales-Angulo, A. M., Huang, E. H. és mtsai: Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2007, 68, 1004-1009.
48. Overgaard, M., Nielsen, H. M., Overgaard, J.: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother. Oncol., 2007, 82, 247-253.
49. Kyndi, M., Overgaard, M., Nielsen, H. M. és mtsai: High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c. Radiother. Oncol., 2009, 90, 74-79.
50. Kyndi, M., Sorensen, F. B., Knudsen, H. és mtsai: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J. Clin. Oncol., 2008, 26, 1419-1426.
51. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 2005, 365, 1687-1717.
52. Schnitt, S. J.: Traditional and newer pathologic factors. J. Natl. Cancer Inst. Monogr., 2001, 30, 22-26.
53. Fisher, B., Dignam, J., Wolmark, N. és mtsai: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 1999, 353, 1993-2000.
54. Houghton, J., George, W. D., Cuzick, J. és mtsai: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 2003, 362, 95-102.
55. Cuzick, J.: Treatment for DCIS - results from clinical trials. Surg. Oncol., 2003, 12, 213-219.
56. Swain, S. M., Wilson, J. W., Mamounas, E. P. és mtsai: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J. Natl. Cancer Inst., 2004, 96, 516-523.
57. Berry, D., Cirrincione, C., Henderson, I. C. és mtsai: Estrogenreceptor status and outcomes of modern chemotherapy for patients with node positive breast cancer. JAMA, 2006, 295, 516-523.
58. Albain, K., Barlow, W., O'Malley, F. és mtsai: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fl uorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 (abstract). San Antonio TX, 2004, LBA37.
59. De Laurentiis, M., Arpino, G., Massarelli, E. és mtsai: A metaanalysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res., 2005, 11, 4741-4748.
60. Dowsett, M., Allred, C., Knox, J. és mtsai: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol., 2008, 26, 1059-1065.
61. Paik, S., Bryant, J., Tan-Chiu, E. és mtsai: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl. Cancer Inst., 2000, 92, 1991-1998.
62. Mamounas, E. P., Bryant, J., Lembersky, B. és mtsai: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol., 2005, 23, 3686-3696.
63. Perez, E. A., Romond, E. H., Suman, V. J. és mtsai: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J. Clin. Oncol., 2007, 25, 512.
64. Romond, E. H., Perez, E. A., Bryant, J. és mtsai: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med., 2005, 353, 1673-1684.
65. Untch, M., Gelber, R. D., Jackisch, C. és mtsai: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann. Oncol., 2008, 19, 1090-1096.
66. Pierce, L. J., Levin, A. M., Rebbeck, T. R. és mtsai: Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol., 2006, 24, 2437-2443.
67. American College of Obstetrics and Gynecology Committee on Gynecological Practice. Tamoxifen and uterine cancer. ACOG Committee Opinion, 2006, 336, 1-4.
68. Hillner, B. E., Ingle, J. N., Chelebowski, R. T. és mtsai: American Society of Clinical Oncology 2003 Update on the role of biphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol., 2003, 21, 4042-4057.
69. Fodor, J., Major, T., Polgár, Cs. és mtsai: Prognosis of patients with local recurrence after mastectomy or conservative surgery for early-stage invasive breast cancer. Breast, 2008, 17, 302-308.
70. Changpar, A., Meric-Bernstam, F., Hunt, K. K. és mtsai: Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann. Surg. Oncol., 2003, 10, 628-634.
71. Haffty, B. G., Hauser, A., Choi, D. H. és mtsai: Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer, 2004, 100 , 252-263.
72. Kurtz, J. M., Amalric, R., Brandone, H. és mtsai: Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer, 1989, 63, 1912-1917.
73. Komoike, Y., Akiyama, F., Iino, Y. és mtsai: Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classifi cation of true recurrences and new primary tumors. Breast Cancer, 2005, 12, 104-111.
74. Parikh, R. R., Housman, D., Yang, Q. és mtsai: Prognostic value of triple-negative phenotype at the time of locally recurrent conservatively treated breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72, 1056-1063.
75. Fodor J., Gulyás G., Polgár Cs. és mtsai: Sugárterápia és emlohelyreállító mutét: az összeférhetoség kérdése. Orv. Hetil., 2003, 144, 549-555.
76. Whitfi eld, G. A., Horan, G., Irwin, M. S. és mtsai: Incidence of severe capsular contracture following implant-based immediate breast reconstruction with or without postoperative chest wall radiotherapy using 40 Gray in 15 fractions. Radiother. Oncol., 2009, 90, 141-147.
77. Anathakrishnan, P., Lucas, A.: Options and considerations in timing of breast reconstruction after mastectomy. Cleve. Clin. J. Med., 2008, 75, 30-33.